icon
موقع حكومي رسمي تابع لحكومة المملكة العربية السعودية
icon الجمعة 12 جمادى الأولى 1448هـ
نسخة تجريبية
icon
روابط المواقع الالكترونية الرسمية السعودية تنتهي بـ gov.sa

جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa

icon
المواقع الرسمية الآمنة تستخدم HTTPS

تحقق من أن الموقع يستخدم بروتوكول HTTPS

icon

مسجل لدى هيئة الحكومة الرقمية برقم :

20250831619
اقتراحات

قائمة الدراسات السريرية المسجلة على الادوية

عرض 291 - 300 من 518
عنوان الدراسة داعم الدراسة حالة الدراسة دواء الدراسة مرحلة الدراسة رقم بروتوكول الدراسة موقع الدراسة
An observational, prospective cohort study to evaluate the safety and effectiveness of Remsima® in the treatment of inflammatory bowel disease among Saudi Arabia patients diagnosed with Crohn’s disease, ulcerative colitis, or fistulizing CD Hikma Pharmaceuticals Ongoing Remsima 4 RMS-KSA-20 King Abdulaziz University Hospital (Jeddah)
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma SWOG (Southwest Oncology Group) Ongoing Ibrutinib 3 A051301 King Faisal Specialist Hospital and Research Center (Riyadh)
Randomized, two-way, two-period, single injectable dose, open-label, crossover, bioequivalence study to compare Enoxa pre-filled syringes (80 mg enoxaparin sodium) versus Clexane® pre-filled syringes (80 mg enoxaparin sodium), in healthy subjects under fasting condition. MEDIS Laboratories Ongoing Enoxa / Enoxaparin BE 21-2017 v.02 Saudi Ajal
OPEN LABEL, RANDOMIZED, SINGLE SITE CLINICAL TRIAL TO COMPARE THE SAFETY & EFFICACY OF HERBAL MELANIN EXTRACTED FROM NIGELLA SATIVA SEEDS VS STANDARD OF CARE TREATMENT IN TREATING GASTRITIS PATIENTS KAIMRC Rejected Melanole NIGELLA SATIVA 2 RC15/152/R N/A
ATOS study_A 12–month prospective observational study assessing the real-world clinical effectiveness, safety and health-economic benefits of Toujeo® initiation after oral antidiabetic drug failure in insulin-naïve patients with type 2 diabetes mellitus SANOFI Ongoing TOUJEO 4 OBS14708 King Abdulaziz University Hospital (Jeddah), Dr. Ghassan N. Pharaon General Hospital (Jeddah), Dallah Hospital (Riyadh), Alzafer Hospital (Najran), Dr. Bakhsh Hospital (Jeddah), Saudi German Hospital (Jeddah), Arrawdha General Hospital (Dammam), Almana Hospital (Jubail), Almouwasat Hospital (Dammam), Specialized Medical Center (Riyadh)
"A 12-week, multicenter, randomized, double-blind, placebo-controlledstudy to assess the efficacy and safety of QAW039 when added tostandard-of-care asthma therapy in patients with uncontrolled asthma" Novartis Ongoing QAW039/Fevipiprant 3 CQAW039A2316 King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah)
"A 2-treatment period, randomized, placebo-controlled,multicenter parallel-group study to assess the safety ofQAW039 when added to existing asthma therapy in GINAsteps 3, 4 and 5 patients with uncontrolled asthma" Novartis Ongoing QAW039/Fevipiprant 3 CQAW039A2315 King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah)
Randomized, four-way, four-period, single oral dose, open-label, crossover, bioequivalence study to compare Tacrolimus Immediate-release capsules (5 mg tacrolimus) versus Prograf® Immediate-release capsules (5 mg tacrolimus), in healthy subjects under fasting conditions. MEDIS Laboratories Ongoing Tacrolimus/ Prograf BE 19-2017 Saudi Ajal
"A PHASE III, MULTICENTER,RANDOMISED, DOUBLEBLIND,PLACEBOCONTROLLEDSTUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER" Roche Ongoing ATEZOLIZUMAB / PACLITAXEL 3 MO39196 International Medical Center (Jeddah), King Fahad Specialist Hospital (Dammam), King Fahad Medical City (Riyadh)
A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Endocrine Therapy Alone in Patients with High Risk Node Positive Early Stage Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer Eli Lilly Ongoing abemaciclib 3 I3Y-MC-JPCF King Fahad Medical City (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam)